Emcure Pharmaceuticals Acquires Remaining Stake in Gennova Biopharmaceuticals, Paving Way for Wholly-Owned Subsidiary Status
Emcure Pharmaceuticals Ltd has announced the acquisition of remaining shares in Gennova Biopharmaceuticals Limited, a subsidiary company. The transaction involves purchasing 663,865 Equity Shares from all individual shareholders, with the move set to make Gennova a wholly-owned subsidiary of Emcure.The acquisition details confirm that Emcure will now hold 100% control over Gennova. Prior to this purchase, Emcure held an 87.95% stake in Gennova.
The total consideration for the acquisition is Rs. 2,318.7 Million, payable in cash across one or more tranches upon closing. The company has entered into Share Purchase Agreements with all individual shareholders regarding the transfer of these shares.
Emcure expects to complete the acquisition on or before July 31, 2026.
Gennova’s Background and Financial Standing
Gennova Biopharmaceuticals Limited operates in the pharmaceuticals industry, focusing on the research, development, manufacturing, and marketing of biotechnology-based products.Incorporated on June 19, 2001, the entity has undergone several name changes throughout its history, starting as Emcure Dragon Biotech Limited before becoming Gennova Biopharmaceuticals Limited on February 15, 2006.
Gennova is currently a subsidiary of Emcure Pharmaceuticals Ltd. The transaction aligns with Emcure's existing relationship with the target entity, as both companies are classified as related parties.
A summary of Gennova’s operational and financial performance is provided below:
| Metric | Detail |
|---|---|
| Industry | Pharmaceuticals |
| Current Stake Held by Emcure | 87.95% |
| Shares Acquired in This Transaction | 663,865 (12.05% of total issued and paid up capital) |
| Post-Acquisition Shareholding | 100% |
Financial Performance and Company Details
The financial performance data for Gennova, along with its operational details, is summarized as follows:| Detail | Information |
|---|---|
| Registered Office | Plot No. P-1 & P-2, IT - BT Park, Phase II, M.I.D.C, Hinjawadi, Pune - 411057, Maharashtra, India |
| Nature of Business | Research and development, manufacturing and marketing of biotechnology-based products. |
| Date of Incorporation | June 19, 2001 |
| Turnover (FY ended March 31, 2026) | Rs. 4,917.42 Million |
| PAT (FY ended March 31, 2026) | Rs. 54.25 Million |
Previous years' turnover for Gennova includes FY 2025-26 at Rs. 4,917.42 Million, FY 2024-25 at Rs. 4,299.46 Million, and FY 2023-24 at Rs. 4,220.82 Million. The company operates in India.
EMCURE Stock Price Movement
Emcure Pharmaceuticals Limited shares slipped today, shedding 1.40% and settling at ₹1793.3 in the post-market session. The stock traded within its day’s range, seeing a low of ₹1785.5 amid total trading volume amounting to 87,267 shares.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.